STADA set to expand Specialty portfolio with positive CHMP opinion on Kinpeygo orphan medicine for IgAN kidney disease

STADA and Xbrane secure EU approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis®

STADA delivers double-digit growth in 2019 as it invests to lead Consumer Healthcare and Generics core segments